New therapeutic approach to the hirsute patient.
Spironolactone, an aldosterone antagonist currently used in the treatment of hypertension, has numerous antiandrogenic side effects. Decreased production rates of testosterone in intact (N = 10) and hirsute (N = 6) women, respectively, were noted after short (7 days) or long-term (6 months) administration of the drug, 25 mg twice daily. A 50% diminution in the urinary 17-ketosteroid excretion was also observed after 6 months of therapy. Assessment of the treatment was done by the patients: a reduction in hair growth rate was initially observed after 3 to 4 months, followed by the appearance of a more downy type of new growth and a decrease in diameter of the hair shaft. It is concluded that this beneficial effect is obtained by a decrease in the testosterone production rate and probably through competitive inhibition of spironolactone and/or canrenone with the androgen receptor in human hair follicles.
D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006197:Hair / Q000254:growth & development; D006628:Hirsutism / Q000188:drug therapy*; D006801:Humans; D011944:Receptors, Androgen; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use*; D013739:Testosterone / Q000378:metabolism; D013997:Time Factors
D015068:17-Ketosteroids; D011944:Receptors, Androgen; D013148:Spironolactone; D013739:Testosterone